Company Overview - Galectin Therapeutics Inc. is focused on developing therapeutics targeting galectin-3 for patients with metabolic dysfunction-associated steatohepatitis (MASH) cirrhosis and portal hypertension [1][8] - The lead drug, belapectin, is a carbohydrate-based drug that inhibits galectin-3, which is involved in inflammatory, fibrotic, and malignant diseases [8] Upcoming Event - A virtual key opinion leader (KOL) event is scheduled for June 16, 2025, to discuss the unmet needs and treatment landscape for MASH cirrhosis and portal hypertension [1][2] - The event will feature results from the NAVIGATE Phase 3 clinical trial evaluating belapectin for MASH cirrhosis and portal hypertension, highlighting its potential as the first treatment for this condition [2] Clinical Significance - There are currently no approved therapies to prevent or treat varices in MASH cirrhosis, making belapectin a significant potential treatment option [2] - The event will include a live Q&A session following the presentations, allowing for further discussion on the findings [3] Key Opinion Leaders - Featured KOLs include Dr. Naga P. Chalasani, a prominent figure in gastroenterology and hepatology, and Dr. Naim Alkhouri, an expert in MASH therapeutics [4][5][7] - Both KOLs have extensive backgrounds in research and clinical practice, contributing to the credibility of the event and the findings presented [4][5] Research and Development Focus - Galectin Therapeutics is dedicated to addressing significant medical needs in chronic liver disease and cancer, with belapectin being central to its development program [8] - The company is also exploring additional development programs in combination immunotherapy for advanced cancers, dependent on finding suitable partnerships [8]